ArticlePhysics and imaging in radiation oncology2026
Isotoxic stereotactic reirradiation for recurrent pelvic cancers.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Reirradiation is clinically challenging, requiring a balance between delivery of dose to tumour while respecting cumulative organ at risk (OAR) dose constraints. Standard prescriptions are often conservative, ignoring patient variability in achievable OAR doses. Isotoxic radiotherapy individualises treatment by delivering the highest equieffective dose in 2 Gy per fraction (EQD2Gy) while meeting OAR constraints. This technical feasibility study assessed isotoxic pelvic reirradiation using cumulative OAR constraints, the original dose distribution as background, and voxel-by-voxel EQD2Gy optimisation. Materials and methods: Data from 30 patients previously treated with pelvic stereotactic body radiotherapy (SBRT) at three UK centres were included. OARs were delineated on both previous and reirradiation image sets and deformably registered. Previous dose was mapped to the current image set and used as background dose for SBRT planning, following published methods. Initial 25 Gy in five fractions (25 Gy/5#) plans were generated for all patients, with further isotoxic dose escalation conducted up to a maximum of 50 Gy (fraction number fixed) until cumulative EQD2Gy constraints were reached. Results: For 25 of 30 patients, clinically acceptable isotoxic plans were obtained, with 23 exceeding the standard UK reirradiation prescription dose of 30 Gy/5#. The median isotoxic prescription was 42 Gy/5#, with four patient plans reaching the upper evaluated limit of 50 Gy. Vessels and the sacral plexus were most frequently dose limiting. Conclusion: This study highlighted the feasibility of isotoxic pelvic reirradiation and supports further investigation into automation and prediction models to streamline implementation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.